Published in Physician Law Weekly, September 29th, 2004
All of the shares will be sold by the company.
The lead underwriter for the offering is Merrill Lynch, Pierce, Fenner & Smith, Inc. The offering will be made only by means of a prospectus.
Corus is a biopharmaceutical company focused on the development and commercialization of applications and formulations of known therapeutics to treat severe respiratory diseases.
This article was prepared by Physician Law Weekly editors from...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Physician Law Weekly